Administration of a gonadotropin-releasing hormone agonist during pregnancy: follow-up of 28 pregnancies exposed to triptoreline.
OBJECTIVE
To evaluate the teratogenic or fetal risk of a long-acting GnRH agonist (GnRH-a) triptoreline acetate (Decapeptyl; Ipsen-Biotech, Inc., Paris, France), inadvertently administrated in the first weeks of pregnancy.


METHODS
Prospective follow-up of exposed pregnancies and case reports.


METHODS
Teratology information service of a public hospital and pharmacovigilance department of the firm.


METHODS
Inadvertent pregnant women receiving a treatment, mainly for endometriosis or IVF.


METHODS
Case by case, individual estimations of the risks have been provided.


METHODS
Each pregnancy issue has been analyzed.


RESULTS
No teratogenic or fetal toxic effect has been noted.


CONCLUSIONS
No specific hazard has been observed among newborns after inadvertent exposures to a GnRH-a during the first 20 weeks of pregnancy.
Elefant
E
E
Centre de Renseignements sur les Agents Tératogènes, Centre Hospitalo-Universitaire Saint-Antoine, Paris, France.
Biour
B
B
Blumberg-Tick
J
J
Roux
C
C
Thomas
F
F
D000014:Abnormalities, Drug-Induced; D005260:Female; D005313:Fetal Death / Q000139:chemically induced; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011446:Prospective Studies; D012307:Risk Factors; D017329:Triptorelin Pamoate / Q000009:adverse effects*
D017329:Triptorelin Pamoate